Table 1. Demographics and clinical presentation of subjects studied.
Subject/Gender | Age | Trigeminal division affected | Laterality | Medications | Effect of treatment | Post GKRS numbness | Post treatment MR gadolinium enhancement |
S1/F | 43 | V1, V2, V3 | Left | Intolerant/poor effectiveness | Significant improvement initially, pain recurred at 1 year | No | Yes |
S2/F | 77 | V2, V3 | Right | Carbamazepine 800 mg daily | No pain at one year post treatment | No | No |
S3/M | 53 | V1, V2 | Right | Carbamazepine 600 mg daily | No pain at 6 months | No | No |
S4/F | 82 | V2 | Left | Intolerant/poor effectiveness | No pain at 6 months | No | Yes |
S5/F | 83 | V1 | Left | Intolerant/poor effectiveness | No pain at 6 months | No | Yes |